<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD05250000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q96EB6</UniProt_ID>
  <Seq_Length>747</Seq_Length>
  <Molecule_Weight>81681</Molecule_Weight>
  <KEGG_ID>hsa:23411</KEGG_ID>
  <Orthology_ID>K11411</Orthology_ID>
  <EBI_ID>EBI-1802965</EBI_ID>
  <Function_Summary>NAD-dependent protein deacetylase that links transcriptional regulation directly to intracellular energetics and participates in the coordination of several separated cellular functions such as cell cycle, response to DNA damage, metobolism, apoptosis and autophagy. Can modulate chromatin function through deacetylation of histones and can promote alterations in the methylation of histones and DNA, leading to transcriptional repression. Deacetylates a broad range of transcription factors and coregulators, thereby regulating target gene expression positively and negatively. Serves as a sensor of the cytosolic ratio of NAD(+)/NADH which is altered by glucose deprivation and metabolic changes associated with caloric restriction. Is essential in skeletal muscle cell differentiation and in response to low nutrients mediates the inhibitory effect on skeletal myoblast differentiation which also involves 5'-AMP-activated protein kinase (AMPK) and nicotinamide phosphoribosyltransferase (NAMPT). Component of the eNoSC (energy-dependent nucleolar silencing) complex, a complex that mediates silencing of rDNA in response to intracellular energy status and acts by recruiting histone-modifying enzymes. The eNoSC complex is able to sense the energy status of cell: upon glucose starvation, elevation of NAD(+)/NADP(+) ratio activates SIRT1, leading to histone H3 deacetylation followed by dimethylation of H3 at 'Lys-9' (H3K9me2) by SUV39H1 and the formation of silent chromatin in the rDNA locus. Deacetylates 'Lys-266' of SUV39H1, leading to its activation. Inhibits skeletal muscle differentiation by deacetylating PCAF and MYOD1. Deacetylates H2A and 'Lys-26' of HIST1H1E. Deacetylates 'Lys-16' of histone H4 (in vitro). Involved in NR0B2/SHP corepression function through chromatin remodeling: Recruited to LRH1 target gene promoters by NR0B2/SHP thereby stimulating histone H3 and H4 deacetylation leading to transcriptional repression. Proposed to contribute to genomic integrity via positive regulation of telomere length; however, reports on localization to pericentromeric heterochromatin are conflicting. Proposed to play a role in constitutive heterochromatin (CH) formation and/or maintenance through regulation of the available pool of nuclear SUV39H1. Upon oxidative/metabolic stress decreases SUV39H1 degradation by inhibiting SUV39H1 polyubiquitination by MDM2. This increase in SUV39H1 levels enhances SUV39H1 turnover in CH, which in turn seems to accelerate renewal of the heterochromatin which correlates with greater genomic integrity during stress response. Deacetylates 'Lys-382' of p53/TP53 and impairs its ability to induce transcription-dependent proapoptotic program and modulate cell senescence. Deacetylates TAF1B and thereby represses rDNA transcription by the RNA polymerase I. Deacetylates MYC, promotes the association of MYC with MAX and decreases MYC stability leading to compromised transformational capability. Deacetylates FOXO3 in response to oxidative stress thereby increasing its ability to induce cell cycle arrest and resistance to oxidative stress but inhibiting FOXO3-mediated induction of apoptosis transcriptional activity; also leading to FOXO3 ubiquitination and protesomal degradation. Appears to have a similar effect on MLLT7/FOXO4 in regulation of transcriptional activity and apoptosis. Deacetylates DNMT1; thereby impairs DNMT1 methyltransferase-independent transcription repressor activity, modulates DNMT1 cell cycle regulatory function and DNMT1-mediated gene silencing. Deacetylates RELA/NF-kappa-B p65 thereby inhibiting its transactivating potential and augments apoptosis in response to TNF-alpha. Deacetylates HIF1A, FOXO1, KAT5/TIP60, RB1 and HIC1. Inhibits E2F1 transcriptional activity and apoptotic function, possibly by deacetylation. Involved in HES1- and HEY2-mediated transcriptional repression. In cooperation with MYCN seems to be involved in transcriptional repression of DUSP6/MAPK3 leading to MYCN stabilization by phosphorylation at 'Ser-62'. Deacetylates MEF2D. Required for antagonist-mediated transcription suppression of AR-dependent genes which may be linked to local deacetylation of histone H3. Represses HNF1A-mediated transcription. Required for the repression of ESRRG by CREBZF. Modulates AP-1 transcription factor activity. Deacetylates NR1H3 AND NR1H2 and deacetylation of NR1H3 at 'Lys-434' positively regulates transcription of NR1H3:RXR target genes, promotes NR1H3 proteosomal degradation and results in cholesterol efflux; a promoter clearing mechanism after reach round of transcription is proposed. Involved in lipid metabolism. Implicated in regulation of adipogenesis and fat mobilization in white adipocytes by repression of PPARG which probably involves association with NCOR1 and SMRT/NCOR2. Deacetylates ACSS2 leading to its activation, and HMGCS1. Involved in liver and muscle metabolism. Through deacteylation and activation of PPARGC1A is required to activate fatty acid oxidation in skeletel muscle under low-glucose conditions and is involved in glucose homeostasis. Involved in nuclear location and activation of FOXO1 leading to increased gluconeogenesis in liver. Involved in regulation of PPARA and fatty acid beta-oxidation in liver. Involved in positive regulation of insulin secretion in pancreatic beta cells in response to glucose; the function seems to imply transcriptional repression of UCP2. Proposed to deacetylate IRS2 thereby facilitating its insuline-induced tyrosine phosphorylation. Deacetylates SREBF1 isoform SREBP-1C thereby decreasing its stability and transactivation in lipogenic gene expression. Involved in DNA damage response by repressing genes which are involved in DNA repair, such as XPC and TP73, deacetylating XRCC6/Ku70, and faciliting recruitment of additional factors to sites of damaged DNA, such as SIRT1-deacetylated NBN can recruit ATM to initiate DNA repair and SIRT1-deacetylated XPA interacts with RPA2. Also involved in DNA repair of DNA double-strand breaks by homologous recombination and specifically single-strand annealing independently of XRCC6/Ku70 and NBN. Transcriptional suppression of XPC probably involves an E2F4:RBL2 suppressor complex and protein kinase B (AKT) signaling. Transcriptional suppression of TP73 probably involves E2F4 and PCAF. Deacetylates WRN thereby regulating its helicase and exonuclease activities and regulates WRN nuclear translocation in response to DNA damage. Deacetylates APEX1 at 'Lys-6' and 'Lys-7' and stimulates cellular AP endonuclease activity by promoting the association of APEX1 to XRCC1. Increases p53/TP53-mediated transcription-independent apoptosis by blocking nuclear translocation of cytoplasmic p53/TP53 and probably redirecting it to mitochondria. Deacetylates XRCC6/Ku70 at 'Lys-539' and 'Lys-542' causing it to sequester BAX away from mitochondria thereby inhibiting stress-induced apoptosis. Is involved in autophagy, presumably by deacetylating ATG5, ATG7 and MAP1LC3B/ATG8. Deacetylates AKT1 which leads to enhanced binding of AKT1 and PDK1 to PIP3 and promotes their activation. Proposed to play role in regulation of STK11/LBK1-dependent AMPK signaling pathways implicated in cellular senescence which seems to involve the regulation of the acetylation status of STK11/LBK1. Can deacetylate STK11/LBK1 and thereby increase its activity, cytoplasmic localization and association with STRAD; however, the relevance of such activity in normal cells is unclear. In endothelial cells is shown to inhibit STK11/LBK1 activity and to promote its degradation. Deacetylates SMAD7 at 'Lys-64' and 'Lys-70' thereby promoting its degradation. Deacetylates CIITA and augments its MHC class II transacivation and contributes to its stability. Deacteylates MECOM/EVI1. Isoform 2 is shown to deacetylate 'Lys-382' of p53/TP53, however with lower activity than isoform 1. In combination, the two isoforms exert an additive effect. Isoform 2 regulates p53/TP53 expression and cellular stress response and is in turn repressed by p53/TP53 presenting a SIRT1 isoform-dependent auto-regulatory loop. In case of HIV-1 infection, interacts with and deacetylates the viral Tat protein. The viral Tat protein inhibits SIRT1 deacetylation activity toward RELA/NF-kappa-B p65, thereby potentiates its transcriptional activity and SIRT1 is proposed to contribute to T-cell hyperactivation during infection.SirtT1 75 kDa fragment: catalytically inactive 75SirT1 may be involved in regulation of apoptosis. May be involved in protecting chondrocytes from apoptotic death by associating with cytochrome C and interfering with apoptosome assembly.</Function_Summary>
  <Catalytic_Mechanism>NAD(+) + an acetylprotein = nicotinamide + O-acetyl-ADP-ribose + a protein.</Catalytic_Mechanism>
  <Pfam_ID>PF02146:SIR2</Pfam_ID>
  <Allosteric_Activator_Count>27</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>70</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>75SirT1</Alias>
      <Alias>Regulatory protein SIR2 homolog 1</Alias>
      <Alias>SirtT1 75 kDa fragment</Alias>
      <Alias>hSIR2</Alias>
      <Alias>SIR2-like protein 1</Alias>
      <Alias>hSIRT1</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with an identical protein or proteins.</Detail>
      <Keyword>Identical protein binding</Keyword>
      <Ontology_ID>GO:0042802</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with the oxidized form, NAD, of nicotinamide adenine dinucleotide, a coenzyme involved in many redox and biosynthetic reactions.</Detail>
      <Keyword>NAD+ binding</Keyword>
      <Ontology_ID>GO:0070403</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a protein C-terminus, the end of any peptide chain at which the 1-carboxy function of a constituent amino acid is not attached in peptide linkage to another amino-acid residue.</Detail>
      <Keyword>Protein C-terminus binding</Keyword>
      <Ontology_ID>GO:0008022</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with Helix Loop Helix, a domain of 40-50 residues that occurs in specific DNA-binding proteins that act as transcription factors. The domain is formed of two amphipathic helices joined by a variable length linker region that can form a loop and it mediates protein dimerization.</Detail>
      <Keyword>HLH domain binding</Keyword>
      <Ontology_ID>GO:0043398</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the hydrolysis of various bonds, e.g. C-O, C-N, C-C, phosphoric anhydride bonds, etc. Hydrolase is the systematic name for any enzyme of EC class 3.</Detail>
      <Keyword>Hydrolase activity</Keyword>
      <Ontology_ID>GO:0016787</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a histone, any of a group of water-soluble proteins found in association with the DNA of plant and animal chromosomes. They are involved in the condensation and coiling of chromosomes during cell division and have also been implicated in nonspecific suppression of gene activity.</Detail>
      <Keyword>Histone binding</Keyword>
      <Ontology_ID>GO:0042393</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a mitogen-activated protein kinase.</Detail>
      <Keyword>Mitogen-activated protein kinase binding</Keyword>
      <Ontology_ID>GO:0051019</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with a repressing transcription factor and also with the basal transcription machinery in order to stop, prevent, or reduce the frequency, rate or extent of transcription. Cofactors generally do not bind DNA, but rather mediate protein-protein interactions between repressive transcription factors and the basal transcription machinery.</Detail>
      <Keyword>Transcription corepressor activity</Keyword>
      <Ontology_ID>GO:0003714</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with zinc (Zn) ions.</Detail>
      <Keyword>Zinc ion binding</Keyword>
      <Ontology_ID>GO:0008270</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any metal ion.</Detail>
      <Keyword>Metal ion binding</Keyword>
      <Ontology_ID>GO:0046872</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with any of the basic Helix-Loop-Helix (bHLH) superfamily of transcription factors, important regulatory components in transcriptional networks of many developmental pathways.</Detail>
      <Keyword>BHLH transcription factor binding</Keyword>
      <Ontology_ID>GO:0043425</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Catalysis of the reaction: histone H3 N6-acetyl-L-lysine (position 9) + H2O = histone H3 L-lysine (position 9) + acetate. This reaction requires the presence of NAD, and represents the removal of an acetyl group from lysine at position 9 of the histone H3 protein.</Detail>
      <Keyword>NAD-dependent histone deacetylase activity (H3-K9 specific)</Keyword>
      <Ontology_ID>GO:0046969</Ontology_ID>
    </Funtion>
    <Funtion>
      <Detail>Interacting selectively and non-covalently with one of the p53 family of proteins.</Detail>
      <Keyword>P53 binding</Keyword>
      <Ontology_ID>GO:0002039</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>484</Position>
      <Original>Val</Original>
      <Variation>Asp</Variation>
    </Muntion>
    <Muntion>
      <Position>3</Position>
      <Original>Asp</Original>
      <Variation>Glu</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of anti-apoptosis.</Detail>
      <Keyword>Positive regulation of anti-apoptosis</Keyword>
      <Ontology_ID>GO:0045768</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tumor necrosis factor stimulus.</Detail>
      <Keyword>Cellular response to tumor necrosis factor</Keyword>
      <Ontology_ID>GO:0071356</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the rate, frequency, or extent of the androgen receptor signaling pathway.</Detail>
      <Keyword>Negative regulation of androgen receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0060766</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process, such as recognition of nutrient depletion, that activates or increases the rate of macroautophagy to bring cytosolic macromolecules to the vacuole/lysosome for degradation.</Detail>
      <Keyword>Positive regulation of macroautophagy</Keyword>
      <Ontology_ID>GO:0016239</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A form of programmed cell death that begins when a cell receives internal or external signals that trigger the activity of proteolytic caspases, proceeds through a series of characteristic stages typically including rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), and plasma membrane blebbing (but maintenance of its integrity until the final stages of the process), and ends with the death of the cell.</Detail>
      <Keyword>Apoptosis</Keyword>
      <Ontology_ID>GO:0006915</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular metabolic process in which a cell duplicates one or more molecules of DNA. DNA replication begins when specific sequences, known as origins of replication, are recognized and bound by initiation proteins, and ends when the original DNA molecule has been completely duplicated and the copies topologically separated. The unit of replication usually corresponds to the genome of the cell, an organelle, or a virus. The template for replication can either be an existing DNA molecule or RNA.</Detail>
      <Keyword>DNA replication</Keyword>
      <Ontology_ID>GO:0006260</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Regulation of transcription</Keyword>
      <Ontology_ID>GO:0045449</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The release of triglycerides, any triester of glycerol, from storage within cells or tissues, making them available for metabolism.</Detail>
      <Keyword>Triglyceride mobilization</Keyword>
      <Ontology_ID>GO:0006642</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of transcription from an RNA polymerase II promoter.</Detail>
      <Keyword>Negative regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0000122</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Progression of the cell from its inception to the end of its lifespan.</Detail>
      <Keyword>Cell aging</Keyword>
      <Ontology_ID>GO:0007569</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of prostaglandin.</Detail>
      <Keyword>Negative regulation of prostaglandin biosynthetic process</Keyword>
      <Ontology_ID>GO:0031393</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a hydrogen peroxide (H2O2) stimulus.</Detail>
      <Keyword>Cellular response to hydrogen peroxide</Keyword>
      <Ontology_ID>GO:0070301</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate, or extent of smooth muscle cell apoptosis.</Detail>
      <Keyword>Regulation of smooth muscle cell apoptosis</Keyword>
      <Ontology_ID>GO:0034391</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a ionizing radiation stimulus. Ionizing radiation is radiation with sufficient energy to remove electrons from atoms and may arise from spontaneous decay of unstable isotopes, resulting in alpha and beta particles and gamma rays. Ionizing radiation also includes X-rays.</Detail>
      <Keyword>Cellular response to ionizing radiation</Keyword>
      <Ontology_ID>GO:0071479</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of RNA on a template of DNA.</Detail>
      <Keyword>Transcription, DNA-dependent</Keyword>
      <Ontology_ID>GO:0006351</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the rate or extent of cell proliferation.</Detail>
      <Keyword>Positive regulation of cell proliferation</Keyword>
      <Ontology_ID>GO:0008284</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of the muscle over time, from its formation to the mature structure. The muscle is an organ consisting of a tissue made up of various elongated cells that are specialized to contract and thus to produce movement and mechanical work.</Detail>
      <Keyword>Muscle organ development</Keyword>
      <Ontology_ID>GO:0007517</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of fatty acid within an organism or cell.</Detail>
      <Keyword>Fatty acid homeostasis</Keyword>
      <Ontology_ID>GO:0055089</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of addition of phosphate groups to amino acids within a protein.</Detail>
      <Keyword>Positive regulation of protein phosphorylation</Keyword>
      <Ontology_ID>GO:0001934</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cellular homeostatic process involved in the maintenance of an internal steady state of glucose within a cell or between a cell and its external environment.</Detail>
      <Keyword>Cellular glucose homeostasis</Keyword>
      <Ontology_ID>GO:0001678</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage and resulting in the initiation of apoptosis (programmed cell death).</Detail>
      <Keyword>DNA damage response, signal transduction by p53 class mediator resulting in induction of apoptosis</Keyword>
      <Ontology_ID>GO:0042771</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of endodeoxyribonuclease activity, the hydrolysis of ester linkages within deoxyribonucleic acid by creating internal breaks.</Detail>
      <Keyword>Regulation of endodeoxyribonuclease activity</Keyword>
      <Ontology_ID>GO:0032071</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of macrophage apoptosis.</Detail>
      <Keyword>Positive regulation of macrophage apoptosis</Keyword>
      <Ontology_ID>GO:2000111</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The repair of single strand breaks in DNA. Repair of such breaks is mediated by the same enzyme systems as are used in base excision repair.</Detail>
      <Keyword>Single strand break repair</Keyword>
      <Ontology_ID>GO:0000012</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the rate, frequency or extent of glucose metabolism. Glucose metabolic processes are the chemical reactions and pathways involving glucose, the aldohexose gluco-hexose.</Detail>
      <Keyword>Regulation of glucose metabolic process</Keyword>
      <Ontology_ID>GO:0010906</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of triglyceride within a cell or between a cell and its external environment.</Detail>
      <Keyword>Cellular triglyceride homeostasis</Keyword>
      <Ontology_ID>GO:0035356</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of transcription from the RNA polymerase II promoter.</Detail>
      <Keyword>Positive regulation of transcription from RNA polymerase II promoter</Keyword>
      <Ontology_ID>GO:0045944</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents or decreases the rate of addition of phosphate groups to a molecule.</Detail>
      <Keyword>Negative regulation of phosphorylation</Keyword>
      <Ontology_ID>GO:0042326</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which a relatively unspecialized cell acquires specialized features of a white adipocyte, an animal connective tissue cell involved in energy storage. White adipocytes have cytoplasmic lipids arranged in a unique vacuole.</Detail>
      <Keyword>White fat cell differentiation</Keyword>
      <Ontology_ID>GO:0050872</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level.</Detail>
      <Keyword>Cellular response to hypoxia</Keyword>
      <Ontology_ID>GO:0071456</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the conversion of a primary ribosomal RNA (rRNA) transcript into one or more mature rRNA molecules.</Detail>
      <Keyword>RRNA processing</Keyword>
      <Ontology_ID>GO:0006364</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The modification of histone H3 by the removal of one or more acetyl groups.</Detail>
      <Keyword>Histone H3 deacetylation</Keyword>
      <Ontology_ID>GO:0070932</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of bile acids.</Detail>
      <Keyword>Regulation of bile acid biosynthetic process</Keyword>
      <Ontology_ID>GO:0070857</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of chromatin silencing.</Detail>
      <Keyword>Positive regulation of chromatin silencing</Keyword>
      <Ontology_ID>GO:0031937</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the cascade of processes induced by the cell cycle regulator phosphoprotein p53, or an equivalent protein, in response to the detection of DNA damage.</Detail>
      <Keyword>Negative regulation of DNA damage response, signal transduction by p53 class mediator</Keyword>
      <Ontology_ID>GO:0043518</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptosis.</Detail>
      <Keyword>Negative regulation of apoptosis</Keyword>
      <Ontology_ID>GO:0043066</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The chemical reactions and pathways resulting in the breakdown of a protein or peptide by hydrolysis of its peptide bonds, initiated by the covalent attachment of ubiquitin, and mediated by the proteasome.</Detail>
      <Keyword>Proteasomal ubiquitin-dependent protein catabolic process</Keyword>
      <Ontology_ID>GO:0043161</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops or reduces the activity of a helicase.</Detail>
      <Keyword>Negative regulation of helicase activity</Keyword>
      <Ontology_ID>GO:0051097</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The initial formation of a transcriptionally silent chromatin structure such as heterochromatin.</Detail>
      <Keyword>Establishment of chromatin silencing</Keyword>
      <Ontology_ID>GO:0006343</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The biological process whose specific outcome is the progression of a multicellular organism over time from an initial condition (e.g. a zygote or a young adult) to a later condition (e.g. a multicellular animal or an aged adult).</Detail>
      <Keyword>Multicellular organismal development</Keyword>
      <Ontology_ID>GO:0007275</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The acetylation of peptidyl-lysine.</Detail>
      <Keyword>Peptidyl-lysine acetylation</Keyword>
      <Ontology_ID>GO:0018394</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which relatively unspecialized cells, e.g. embryonic or regenerative cells, acquire specialized structural and/or functional features that characterize the cells, tissues, or organs of the mature organism or some other relatively stable phase of the organism's life history. Differentiation includes the processes involved in commitment of a cell to a specific fate and its subsequent development to the mature state.</Detail>
      <Keyword>Cell differentiation</Keyword>
      <Ontology_ID>GO:0030154</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate, or extent of an adaptive immune response.</Detail>
      <Keyword>Positive regulation of adaptive immune response</Keyword>
      <Ontology_ID>GO:0002821</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of adipocyte differentiation.</Detail>
      <Keyword>Negative regulation of fat cell differentiation</Keyword>
      <Ontology_ID>GO:0045599</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the frequency, rate or extent of cholesterol efflux. Cholesterol efflux is the directed movement of cholesterol, cholest-5-en-3-beta-ol, out of a cell or organelle.</Detail>
      <Keyword>Positive regulation of cholesterol efflux</Keyword>
      <Ontology_ID>GO:0010875</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of signaling via the TOR signaling pathway.</Detail>
      <Keyword>Negative regulation of TOR signaling cascade</Keyword>
      <Ontology_ID>GO:0032007</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of an I-kappaB kinase/NF-kappaB induced cascade.</Detail>
      <Keyword>Negative regulation of I-kappaB kinase/NF-kappaB cascade</Keyword>
      <Ontology_ID>GO:0043124</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of nourishment.</Detail>
      <Keyword>Cellular response to starvation</Keyword>
      <Ontology_ID>GO:0009267</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of cell growth.</Detail>
      <Keyword>Negative regulation of cell growth</Keyword>
      <Ontology_ID>GO:0030308</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The process in which one or more ubiquitin groups are added to a protein.</Detail>
      <Keyword>Protein ubiquitination</Keyword>
      <Ontology_ID>GO:0016567</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Repression of transcription of ribosomal DNA by altering the structure of chromatin.</Detail>
      <Keyword>Chromatin silencing at rDNA</Keyword>
      <Ontology_ID>GO:0000183</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of DNA repair.</Detail>
      <Keyword>Positive regulation of DNA repair</Keyword>
      <Ontology_ID>GO:0045739</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The cellular synthesis of either RNA on a template of DNA or DNA on a template of RNA.</Detail>
      <Keyword>Transcription</Keyword>
      <Ontology_ID>GO:0006350</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Repression of transcription by methylation of DNA, leading to the formation of heterochromatin.</Detail>
      <Keyword>Methylation-dependent chromatin silencing</Keyword>
      <Ontology_ID>GO:0006346</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that increases the frequency, rate or extent of insulin receptor signaling.</Detail>
      <Keyword>Positive regulation of insulin receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0046628</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that decreases the stability of a protein, making it more vulnerable to degradative processes or aggregation.</Detail>
      <Keyword>Protein destabilization</Keyword>
      <Ontology_ID>GO:0031648</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The maintenance of chromatin in a transcriptionally silent state such as heterochromatin.</Detail>
      <Keyword>Maintenance of chromatin silencing</Keyword>
      <Ontology_ID>GO:0006344</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the frequency, rate or extent of the peroxisome proliferator activated receptor signaling pathway.</Detail>
      <Keyword>Regulation of peroxisome proliferator activated receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0035358</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The removal of an acetyl group from an acetylated lysine residue in a peptide or protein.</Detail>
      <Keyword>Peptidyl-lysine deacetylation</Keyword>
      <Ontology_ID>GO:0034983</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the protein kinase B signaling cascade, a series of reactions mediated by the intracellular serine/threonine kinase protein kinase B.</Detail>
      <Keyword>Negative regulation of protein kinase B signaling cascade</Keyword>
      <Ontology_ID>GO:0051898</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The repair of UV-induced T-T, C-T, and C-C dimers by the recognition and removal of the damaged DNA strand from the DNA helix as an oligonucleotide. The small gap left in the DNA helix is filled in by the sequential action of DNA polymerase and DNA ligase.</Detail>
      <Keyword>Pyrimidine dimer repair by nucleotide-excision repair</Keyword>
      <Ontology_ID>GO:0000720</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>A change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insulin stimulus. Insulin is a polypeptide hormone produced by the islets of Langerhans of the pancreas in mammals, and by the homologous organs of other organisms.</Detail>
      <Keyword>Response to insulin stimulus</Keyword>
      <Ontology_ID>GO:0032868</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the rate or extent of progress through the mitotic cell cycle.</Detail>
      <Keyword>Regulation of mitotic cell cycle</Keyword>
      <Ontology_ID>GO:0007346</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of the chemical reactions and pathways resulting in the formation of MHC class II.</Detail>
      <Keyword>Positive regulation of MHC class II biosynthetic process</Keyword>
      <Ontology_ID>GO:0045348</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process in which an organism has an effect on an organism of a different species.</Detail>
      <Keyword>Interspecies interaction between organisms</Keyword>
      <Ontology_ID>GO:0044419</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of any TGF-beta receptor signaling pathway.</Detail>
      <Keyword>Negative regulation of transforming growth factor beta receptor signaling pathway</Keyword>
      <Ontology_ID>GO:0030512</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process involved in the maintenance of an internal steady state of cholesterol within an organism or cell.</Detail>
      <Keyword>Cholesterol homeostasis</Keyword>
      <Ontology_ID>GO:0042632</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Synthesis of DNA that proceeds from the broken 3' single-strand DNA end uses the homologous intact duplex as the template.</Detail>
      <Keyword>DNA synthesis involved in DNA repair</Keyword>
      <Ontology_ID>GO:0000731</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that modulates the vectorial transfer of a protein from the cytoplasm into the nucleus, across the nuclear membrane.</Detail>
      <Keyword>Regulation of protein import into nucleus, translocation</Keyword>
      <Ontology_ID>GO:0033158</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that stops, prevents, or reduces the frequency, rate or extent of the activity of the transcription factor NF-kappaB.</Detail>
      <Keyword>Negative regulation of NF-kappaB transcription factor activity</Keyword>
      <Ontology_ID>GO:0032088</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels.</Detail>
      <Keyword>Angiogenesis</Keyword>
      <Ontology_ID>GO:0001525</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the activity of a caspase, any of a group of cysteine proteases involved in apoptosis.</Detail>
      <Keyword>Positive regulation of caspase activity</Keyword>
      <Ontology_ID>GO:0043280</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <PTM_List>
    <PTM>
      <Position>27</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>719</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>659</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>173</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>398</Position>
      <PTM_Type>S-nitrosocysteine</PTM_Type>
    </PTM>
    <PTM>
      <Position>162</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>14</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>47</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>26</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>530</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>16</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>544</Position>
      <PTM_Type>Phosphothreonine</PTM_Type>
    </PTM>
    <PTM>
      <Position>395</Position>
      <PTM_Type>S-nitrosocysteine</PTM_Type>
    </PTM>
    <PTM>
      <Position>545</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>747</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>535</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>159</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>2</Position>
      <PTM_Type>N-acetylalanine</PTM_Type>
    </PTM>
    <PTM>
      <Position>172</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
    <PTM>
      <Position>661</Position>
      <PTM_Type>Phosphoserine</PTM_Type>
    </PTM>
  </PTM_List>
  <molStructure/>
  <Molecule_Seq>
    <Protein_Seq>MADEAALALQPGGSPSAAGADREAASSPAGEPLRKRPRRDGPGLERSPGEPGGAAPEREVPAAARGCPGAAAAALWREAEAEAAAAGGEQEAQATAAAGEGDNGPGLQGPSREPPLADNLYDEDDDDEGEEEEEAAAAAIGYRDNLLFGDEIITNGFHSCESDEEDRASHASSSDWTPRPRIGPYTFVQQHLMIGTDPRTILKDLLPETIPPPELDDMTLWQIVINILSEPPKRKKRKDINTIEDAVKLLQECKKIIVLTGAGVSVSCGIPDFRSRDGIYARLAVDFPDLPDPQAMFDIEYFRKDPRPFFKFAKEIYPGQFQPSLCHKFIALSDKEGKLLRNYTQNIDTLEQVAGIQRIIQCHGSFATASCLICKYKVDCEAVRGDIFNQVVPRCPRCPADEPLAIMKPEIVFFGENLPEQFHRAMKYDKDEVDLLIVIGSSLKVRPVALIPSSIPHEVPQILINREPLPHLHFDVELLGDCDVIINELCHRLGGEYAKLCCNPVKLSEITEKPPRTQKELAYLSELPPTPLHVSEDSSSPERTSPPDSSVIVTLLDQAAKSNDDLDVSESKGCMEEKPQEVQTSRNVESIAEQMENPDLKNVGSSTGEKNERTSVAGTVRKCWPNRVAKEQISRRLDGNQYLFLPPNRYIFHGAEVYSDSEDDVLSSSSCGSNSDSGTCQSPSLEEPMEDESEIEEFYNGLEDEPDVPERAGGAGFGTDGDDQEAINEAISVKQEVTDMNYPSNKS</Protein_Seq>
    <DNA_Seq>GCATCTCCTCCTCCCTCTCCCCGGGCTCCTACTGGCCTGAGGTTGAGGGCGGCTGGGGGCTCGGGGCAGGCTCCGCGGCGTTCCCCTCCCCACCCCGGCCCTCCGTTCAGCCGCGCTCCTCCGGGGCTGCGGTTCCTACTGCGCGAGCTGCCAGTGGATTCGCTCTTTTCCTCCGTCCGTGGCCCGCCTGGGCGGCCTTGTTCTTTCCGCAGCAGCCAGATAACCTTCTGTTCGGTGATGAAATTATCACTAATGGTTTTCATTCCTGTGAAAGTGATGAGGAGGATAGAGCCTCACATGCAAGCTCTAGTGACTGGACTCCAAGGCCACGGATAGGTGTCTGTTTCATGTGGAATACCTGACTTCAGGTCAAGGGATGGTATTTATGCTCGCCTTGCTGTAGACTTCCCAGATCTTCCAGATCCTCAAGCGATGTTTGATATTGAATATTTCAGAAAAGATCCAAGACCATTCTTCAAGTTTGCAAAGGAAATATATCCTGGACAATTCCAGCCATCTCTCTGTCACAAATTCATAGCCTTGTCAGATAAGGAAGGAAAACTACTTCGCAACTATACCCAGAACATAGACACGCTGGAACAGGTTGCGGGAATCCAAAGGATAATTCAGTGTCATGGTTCCTTTGCAACAGCATCTTGCCTGATTTGTAAATACAAAGTTGACTGTGAAGCTGTACGAGGAGATATTTTTAATCAGGTAGTTCCTCGATGTCCTAGGTGCCCAGCTGATGAACCGCTTGCTATCATGAAACCAGAGATTGTGTTTTTTGGTGAAAATTTACCAGAACAGTTTCATAGAGCCATGAAGTATGACAAAGATGAAGTTGACCTCCTCATTGTTATTGGGTCTTCCCTCAAAGTAAGACCAGTAGCACTAATTCCAAGTTCCATACCCCATGAAGTGCCTCAGATATTAATTAATAGAGAACCTTTGCCTCATCTGCATTTTGATGTAGAGCTTCTTGGAGACTGTGATGTCATAATTAATGAATTGTGTCATAGGTTAGGTGGTGAATATGCCAAACTTTGCTGTAACCCTGTAAAGCTTTCAGAAATTACTGAAAAACCTCCACGAACACAAAAAGAATTGGCTTATTTGTCAGAGTTGCCACCCACACCTCTTCATGTTTCAGAAGACTCAAGTTCACCAGAAAGAACTTCACCACCAGATTCTTCAGTGATTGTCACACTTTTAGACCAAGCAGCTAAGAGTAATGATGATTTAGATGTGTCTGAATCAAAAGGTTGTATGGAAGAAAAACCACAGGAAGTACAAACTTCTAGGAATGTTGAAAGTATTGCTGAACAGATGGAAAATCCGGATTTGAAGAATGTTGGTTCTAGTACTGGGGAGAAAAATGAAAGAACTTCAGTGGCTGGAACAGTGAGAAAATGCTGGCCTAATAGAGTGGCAAAGGAGCAGATTAGTAGGCGGCTTGATGGTAATCAGTATCTGTTTTTGCCACCAAATCGTTACATTTTCCATGGCGCTGAGGTATATTCAGACTCTGAAGATGACGTCTTATCCTCTAGTTCTTGTGGCAGTAACAGTGATAGTGGGACATGCCAGAGTCCAAGTTTAGAAGAACCCATGGAGGATGAAAGTGAAATTGAAGAATTCTACAATGGCTTAGAAGATGAGCCTGATGTTCCAGAGAGAGCTGGAGGAGCTGGATTTGGGACTGATGGAGATGATCAAGAGGCAATTAATGAAGCTATATCTGTGAAACAGGAAGTAACAGACATGAACTATCCATCAAACAAATCATAGTGTAATAATTGTGCAGGTACAGGAATTGTTCCACCAGCATTAGGAACTTTAGCATGTCAAAATGAATGTTTACTTGTGAACTCGATAGAGCAAGGAAACCAGAAAGGTGTAATATTTATAGGTTGGTAAAATAGATTGTTTTTCATGGATAATTTTTAACTTCATTATTTCTGTACTTGTACAAACTCAACACTAACTTTTTTTTTTTTAAAAAAAAAAAGGTACTAAGTATCTTCAATCAGCTGTTGGTCAAGACTAACTTTCTTTTAAAGGTTCATTTGTATGATAAATTCATATGTGTATATATAATTTTTTTTGTTTTGTCTAGTGAGTTTCAACATTTTTAAAGTTTTCAAAAAGCCATCGGAATGTTAAATTAATGTAAAGGGAACAGCTAATCTAGACCAAAGAATGGTATTTTCACTTTTCTTTGTAACATTGAATGGTTTGAAGTACTCAAAATCTGTTACGCTAAACTTTTGATTCTTTAACACAATTATTTTTAAACACTGGCATTTTCCAAAACTGTGGCAGCTAACTTTTTAAAATCTCAAATGACATGCAGTGTGAGTAGAAGGAAGTCAACAATATGTGGGGAGAGCACTCGGTTGTCTTTACTTTTAAAAGTAATACTTGGTGCTAAGAATTTCAGGATTATTGTATTTACGTTCAAATGAAGATGGCTTTTGTACTTCCTGTGGACATGTAGTAATGTCTATATTGGCTCATAAAACTAACCTGAAAAACAAATAAATGCTTTGGAAATGTTTCAGTTGCTTTAGAAACATTAGTGCCTGCCTGGATCCCCTTAGTTTTGAAATATTTGCCATTGTTGTTTAAATACCTATCACTGTGGTAGAGCTTGCATTGATCTTTTCCACAAGTATTAAACTGCCAAAATGTGAATATGCAAAGCCTTTCTGAATCTATAATAATGGTACTTCTACTGGGGAGAGTGTAATATTTTGGACTGCTGTTTTCCATTAATGAGGAGAGCAACAGGCCCCTGATTATACAGTTCCAAAGTAATAAGATGTTAATTGTAATTCAGCCAGAAAGTACATGTCTCCCATTGGGAGGATTTGGTGTTAAATACCAAACTGCTAGCCCTAGTATTATGGAGATGAACATGATGATGTAACTTGTAATAGCAGAATAGTTAATGAATGAAACTAGTTCTTATAATTTATCTTTATTTAAAAGCTTAGCCTGCCTTAAAACTAGAGATCAACTTTCTCAGCTGCAAAAGCTTCTAGTCTTTCAAGAAGTTCATACTTTATGAAATTGCACAGTAAGCATTTATTTTTCAGACCATTTTTGAACATCACTCCTAAATTAATAAAGTATTCCTCTGTTGCTTTAGTATTTATTACAATAAAAAGGGTTTGAAATATAGCTGTTCTTTATGCATAAAACACCCAGCTAGGACCATTACTGCCAGAGAAAAAAATCGTATTGAATGGCCATTTCCCTACTTATAAGATGTCTCAATCTGAATTTATTTGGCTACACTAAAGAATGCAGTATATTTAGTTTTCCATTTGCATGATGTTTGTGTGCTATAGATGATATTTTAAATTGAAAAGTTTGTTTTAAATTATTTTTACAGTGAAGACTGTTTTCAGCTCTTTTTATATTGTACATAGTCTTTTATGTAATTTACTGGCATATGTTTTGTAGACTGTTTAATGACTGGATATCTTCCTTCAACTTTTGAAATACAAAACCAGTGTTTTTTACTTGTACACTGTTTTAAAGTCTATTAAAATTGTCATTTGACTTTTTTCTGTTAACTTAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Widely expressed</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nuclear inner membrane</CellLocal>
      <Ontology_ID>GO:0005637</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleus</CellLocal>
      <Ontology_ID>GO:0005634</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Mitochondrion</CellLocal>
      <Ontology_ID>GO:0005739</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nuclear euchromatin</CellLocal>
      <Ontology_ID>GO:0005719</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>RDNA heterochromatin</CellLocal>
      <Ontology_ID>GO:0033553</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nuclear heterochromatin</CellLocal>
      <Ontology_ID>GO:0005720</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Nucleolus</CellLocal>
      <Ontology_ID>GO:0005730</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cytoplasm</CellLocal>
      <Ontology_ID>GO:0005737</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>PML body</CellLocal>
      <Ontology_ID>GO:0016605</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Chromatin silencing complex</CellLocal>
      <Ontology_ID>GO:0005677</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>SIRT1</Gene_Name>
    <Gene_Alias>SIR2L1</Gene_Alias>
    <Gene_ID>23411</Gene_ID>
    <Genbank_ACCN>NM_001142498</Genbank_ACCN>
    <Protein_ACCN>NP_001135970</Protein_ACCN>
    <HGNC_ID>14929</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/23411</Gene_URL>
    <UCSC_ID>uc001jnd.3</UCSC_ID>
    <EMBL_ID>ENSG00000096717</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>Q60644</Uniprot_ID>
      <Gene_Name>Nr1h2</Gene_Name>
      <EBI_ID>EBI-5276809</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-5276809</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q86WX3</Uniprot_ID>
      <Gene_Name>RPS19BP1</Gene_Name>
      <EBI_ID>EBI-4479407</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-4479407</PPI_EBI_URL>
      <Experiment_Number>9</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P68400</Uniprot_ID>
      <Gene_Name>CSNK2A1</Gene_Name>
      <EBI_ID>EBI-347804</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-347804</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9Z0Y9</Uniprot_ID>
      <Gene_Name>Nr1h3</Gene_Name>
      <EBI_ID>EBI-5276764</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-5276764</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q04724</Uniprot_ID>
      <Gene_Name>TLE1</Gene_Name>
      <EBI_ID>EBI-711424</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-711424</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P12956</Uniprot_ID>
      <Gene_Name>XRCC6</Gene_Name>
      <EBI_ID>EBI-353208</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-353208</PPI_EBI_URL>
      <Experiment_Number>7</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q14192</Uniprot_ID>
      <Gene_Name>FHL2</Gene_Name>
      <EBI_ID>EBI-701903</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-701903</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q12778</Uniprot_ID>
      <Gene_Name>FOXO1</Gene_Name>
      <EBI_ID>EBI-1108782</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-1108782</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q14469</Uniprot_ID>
      <Gene_Name>HES1</Gene_Name>
      <EBI_ID>EBI-2832522</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-2832522</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P04637</Uniprot_ID>
      <Gene_Name>TP53</Gene_Name>
      <EBI_ID>EBI-366083</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-366083</PPI_EBI_URL>
      <Experiment_Number>13</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O54864</Uniprot_ID>
      <Gene_Name>Suv39h1</Gene_Name>
      <EBI_ID>EBI-302230</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-302230</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q03112</Uniprot_ID>
      <Gene_Name>MECOM</Gene_Name>
      <EBI_ID>EBI-1384862</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-1384862</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q13085</Uniprot_ID>
      <Gene_Name>ACACA</Gene_Name>
      <EBI_ID>EBI-717681</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-717681</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O60934</Uniprot_ID>
      <Gene_Name>NBN</Gene_Name>
      <EBI_ID>EBI-494844</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-494844</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P26358</Uniprot_ID>
      <Gene_Name>DNMT1</Gene_Name>
      <EBI_ID>EBI-719459</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-719459</PPI_EBI_URL>
      <Experiment_Number>11</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P31749</Uniprot_ID>
      <Gene_Name>AKT1</Gene_Name>
      <EBI_ID>EBI-296087</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-296087</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P10276</Uniprot_ID>
      <Gene_Name>RARA</Gene_Name>
      <EBI_ID>EBI-413374</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-413374</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P42345</Uniprot_ID>
      <Gene_Name>MTOR</Gene_Name>
      <EBI_ID>EBI-359260</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-359260</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q60974</Uniprot_ID>
      <Gene_Name>Ncor1</Gene_Name>
      <EBI_ID>EBI-349004</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-349004</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O15350</Uniprot_ID>
      <Gene_Name>TP73</Gene_Name>
      <EBI_ID>EBI-389606</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-389606</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q13573</Uniprot_ID>
      <Gene_Name>SNW1</Gene_Name>
      <EBI_ID>EBI-632715</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-632715</PPI_EBI_URL>
      <Experiment_Number>7</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q09472</Uniprot_ID>
      <Gene_Name>EP300</Gene_Name>
      <EBI_ID>EBI-447295</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-447295</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9NS37</Uniprot_ID>
      <Gene_Name>CREBZF</Gene_Name>
      <EBI_ID>EBI-632965</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-632965</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q8N163</Uniprot_ID>
      <Gene_Name>KIAA1967</Gene_Name>
      <EBI_ID>EBI-355410</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-355410</PPI_EBI_URL>
      <Experiment_Number>9</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P36956-3</Uniprot_ID>
      <Gene_Name>SREBF1</Gene_Name>
      <EBI_ID>EBI-948338</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-948338</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9HAN9</Uniprot_ID>
      <Gene_Name>NMNAT1</Gene_Name>
      <EBI_ID>EBI-3917542</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-3917542</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q02577</Uniprot_ID>
      <Gene_Name>NHLH2</Gene_Name>
      <EBI_ID>EBI-5378683</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-5378683</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P01106</Uniprot_ID>
      <Gene_Name>MYC</Gene_Name>
      <EBI_ID>EBI-447544</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-447544</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O43159</Uniprot_ID>
      <Gene_Name>RRP8</Gene_Name>
      <EBI_ID>EBI-2008793</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-2008793</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9Y4H2</Uniprot_ID>
      <Gene_Name>IRS2</Gene_Name>
      <EBI_ID>EBI-1049582</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-1049582</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P23025</Uniprot_ID>
      <Gene_Name>XPA</Gene_Name>
      <EBI_ID>EBI-295222</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-295222</PPI_EBI_URL>
      <Experiment_Number>8</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P27986</Uniprot_ID>
      <Gene_Name>PIK3R1</Gene_Name>
      <EBI_ID>EBI-79464</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-79464</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q15466</Uniprot_ID>
      <Gene_Name>NR0B2</Gene_Name>
      <EBI_ID>EBI-3910729</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-3910729</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q04206</Uniprot_ID>
      <Gene_Name>RELA</Gene_Name>
      <EBI_ID>EBI-73886</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-73886</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q01094</Uniprot_ID>
      <Gene_Name>E2F1</Gene_Name>
      <EBI_ID>EBI-448924</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-448924</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P51610</Uniprot_ID>
      <Gene_Name>HCFC1</Gene_Name>
      <EBI_ID>EBI-396176</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-396176</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q14191</Uniprot_ID>
      <Gene_Name>WRN</Gene_Name>
      <EBI_ID>EBI-368417</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-368417</PPI_EBI_URL>
      <Experiment_Number>9</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P33076</Uniprot_ID>
      <Gene_Name>CIITA</Gene_Name>
      <EBI_ID>EBI-1538819</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-1538819</PPI_EBI_URL>
      <Experiment_Number>4</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P27695</Uniprot_ID>
      <Gene_Name>APEX1</Gene_Name>
      <EBI_ID>EBI-1048805</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-1048805</PPI_EBI_URL>
      <Experiment_Number>6</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P49815</Uniprot_ID>
      <Gene_Name>TSC2</Gene_Name>
      <EBI_ID>EBI-396587</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-396587</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q92831</Uniprot_ID>
      <Gene_Name>KAT2B</Gene_Name>
      <EBI_ID>EBI-477430</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-477430</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>O43524</Uniprot_ID>
      <Gene_Name>FOXO3</Gene_Name>
      <EBI_ID>EBI-1644164</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-1644164</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P04198</Uniprot_ID>
      <Gene_Name>MYCN</Gene_Name>
      <EBI_ID>EBI-878369</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-878369</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P98177</Uniprot_ID>
      <Gene_Name>FOXO4</Gene_Name>
      <EBI_ID>EBI-4481939</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-4481939</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q9UBP5</Uniprot_ID>
      <Gene_Name>HEY2</Gene_Name>
      <EBI_ID>EBI-750630</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-750630</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>Q8N122</Uniprot_ID>
      <Gene_Name>RPTOR</Gene_Name>
      <EBI_ID>EBI-1567928</EBI_ID>
      <PPI_EBI_URL>EBI-1802965,EBI-1567928</PPI_EBI_URL>
      <Experiment_Number>3</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Xeroderma Pigmentosum, Group D</Disease_Name>
      <Disease_Detail>Xeroderma Pigmentosum</Disease_Detail>
      <Disease_DB>XRD012</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/xeroderma_pigmentosum_group_d?search=SIRT1#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Aortic Valve Disease</Disease_Name>
      <Disease_Detail>Aortic Disease</Disease_Detail>
      <Disease_DB>ART070</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/aortic_valve_disease?search=SIRT1#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Crystal structure of the SIRT1 catalytic domain bound to NAD and an EX527 analog</PDB_Title>
      <PDB_ID>4I5I</PDB_ID>
      <Resolution>2.5</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=4I5I</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>The 2.5 Angstrom crystal structure of the SIRT1 catalytic domain bound to NAD and an EX527 analog reveals a novel mechanism of histone deacetylase inhibition</PubMed_Title>
    </PDB>
  </PDB_List>
  <Network_List>
    <Network>
      <Pathway_ID>ko04922</Pathway_ID>
      <Pathway_Title>Glucagon signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04152</Pathway_ID>
      <Pathway_Title>AMPK signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05206</Pathway_ID>
      <Pathway_Title>MicroRNAs in cancer</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Cancers</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04068</Pathway_ID>
      <Pathway_Title>FoxO signaling pathway</Pathway_Title>
      <Pathway_Class>Environmental Information Processing</Pathway_Class>
      <Pathway_Subclass>Signal transduction</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko04922</Pathway_ID>
      <Pathway_Title>Glucagon signaling pathway</Pathway_Title>
      <Pathway_Class>Organismal Systems</Pathway_Class>
      <Pathway_Subclass>Endocrine system</Pathway_Subclass>
    </Network>
    <Network>
      <Pathway_ID>ko05031</Pathway_ID>
      <Pathway_Title>Amphetamine addiction</Pathway_Title>
      <Pathway_Class>Human Diseases</Pathway_Class>
      <Pathway_Subclass>Substance dependence</Pathway_Subclass>
    </Network>
  </Network_List>
  <Enzyme_Nomenclature_List>
    <Enzyme_Nomenclature>
      <Enzyme_DB_ID>3.5.1.-</Enzyme_DB_ID>
      <Enzyme_DB_URL>http://www.chem.qmul.ac.uk/iubmb/enzyme/EC3/5/1/-.html</Enzyme_DB_URL>
    </Enzyme_Nomenclature>
  </Enzyme_Nomenclature_List>
  <Modulator_List>
    <Modulator>
      <ASD_ID>ASD02820003</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250001</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250002</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250003</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250004</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250005</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250006</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250007</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250008</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250009</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250010</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250011</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250012</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250013</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250014</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250015</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250016</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250017</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250018</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250019</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250020</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250021</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250022</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250023</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250024</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250025</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250026</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250027</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250028</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250029</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250030</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250031</ASD_ID>
      <Modulator_Feature>Activator</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250032</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250033</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250034</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250035</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250036</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250037</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250038</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250039</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250040</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250041</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250042</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250043</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250044</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250045</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250046</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250047</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250048</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250049</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250050</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250051</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250053</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250054</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250055</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250056</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250057</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250058</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250059</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250060</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250061</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250062</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250063</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250064</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250065</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250066</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250067</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250068</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250069</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250070</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250071</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250072</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250073</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250074</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250075</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250076</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250077</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250078</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250079</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250080</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250081</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250083</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250084</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250085</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250086</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250087</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250088</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250091</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250092</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250094</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250096</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250097</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250098</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250099</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250100</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250101</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
    <Modulator>
      <ASD_ID>ASD05250102</ASD_ID>
      <Modulator_Feature>Inhibitor</Modulator_Feature>
    </Modulator>
  </Modulator_List>
  <Create_Date>2012-06-20</Create_Date>
</Organism_Record>